Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Frydenberg

Showing results (151-160 of 182) with videos related to

Pageof 19
Sort By:
Journal of Patient-Reported Outcomes|March 27, 2025
Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SIClaudia Rutherford, Margaret-Ann Tait, Daniel S J Costa, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
European Urology Focus|February 6, 2023
Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional StudyFabio Zattoni, Giancarlo Marra, Alberto Martini, et al.
The Journal of Urology|September 9, 2022
The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional StudyFabio Zattoni, Giancarlo Marra, Veeru Kasivisvanathan, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trialAndrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, et al.
European Urology Focus|July 30, 2017
Development of Indicators to Assess Quality of Care for Prostate CancerNupur Nag, Jeremy Millar, Ian D Davis, et al.
European Urology Oncology|July 18, 2024
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical RegistryChris Bangma, Paul Doan, Lin Zhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2023
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World DatabaseLouise Emmett, Nathan Papa, William Counter, et al.
Science Translational Medicine|February 8, 2019
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancerMatthew J Watt, Ashlee K Clark, Luke A Selth, et al.
Pageof 19

Showing results (151-160 of 182) with videos related to

Sort By:
Pageof 19
Journal of Patient-Reported Outcomes|March 27, 2025
Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SIClaudia Rutherford, Margaret-Ann Tait, Daniel S J Costa, et al.
Lancet (London, England)|March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyMichael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
European Urology Focus|February 6, 2023
Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional StudyFabio Zattoni, Giancarlo Marra, Alberto Martini, et al.
The Journal of Urology|September 9, 2022
The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional StudyFabio Zattoni, Giancarlo Marra, Veeru Kasivisvanathan, et al.
European Urology Oncology|November 29, 2024
Baseline Nodal Status on <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA TrialMichael S Hofman, Veeru Kasivisvanathan, Emma Link, et al.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trialAndrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, et al.
European Urology Focus|July 30, 2017
Development of Indicators to Assess Quality of Care for Prostate CancerNupur Nag, Jeremy Millar, Ian D Davis, et al.
European Urology Oncology|July 18, 2024
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical RegistryChris Bangma, Paul Doan, Lin Zhu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2023
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World DatabaseLouise Emmett, Nathan Papa, William Counter, et al.
Science Translational Medicine|February 8, 2019
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancerMatthew J Watt, Ashlee K Clark, Luke A Selth, et al.
Pageof 19